SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Lion Point Capital, LP

CIK 0001643354 · 375 PARK AVE, SUITE 2609, NEW YORK, NY, 10152 · 212-356-6200

Reported Value
$55M
Q2 2024
Positions
27
Filings on Record
31
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Lion Point Capital, LP reported $55M in U.S.-listed holdings across 27 positions for Q2 2024.

Its largest position, ARDX, represents 11.6% of the portfolio.

Compared with Q1 2024, the fund opened 3 new positions and exited 7.

Portfolio Metrics

Turnover
+7.3%
vs prior filed quarter
Top-10 Concentration
+47.6%
share of reported value
Largest Position
+11.6%
Ardelyx
New / Exited
3 / 7
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $636MQ4 ’18Q1 ’19: $1.1BQ2 ’19: $1.0BQ3 ’19: $897MQ4 ’19: $1.1BQ4 ’19Q1 ’20: $379MQ2 ’20: $412MQ3 ’20: $456MQ4 ’20: $519MQ4 ’20Q1 ’21: $550MQ2 ’21: $579MQ3 ’21: $533MQ4 ’21: $373MQ4 ’21Q1 ’22: $431MQ2 ’22: $878MQ3 ’22: $454MQ4 ’22: $703MQ4 ’22Q1 ’23: $243MQ2 ’23: $221MQ3 ’23: $224MQ4 ’23: $200MQ4 ’23Q1 ’24: $179MQ2 ’24: $55MQ3 ’24: $45MQ4 ’24: $19MQ4 ’24Q1 ’25: $16MQ2 ’25: $15MQ3 ’25: $18MQ4 ’25: $19MQ4 ’25Q1 ’26: $17Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 52.5%ETP: 39.0%Other: 8.6%
  • Common Stock · 52.5% · $29M
  • ETP · 39.0% · $21M
  • Other · 8.6% · $5M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
KINIKSA PHARMACEUTICALS INTLNEW+104.7K104.7K+$2M$2M
BBIOBRIDGEBIO PHARMA INCNEW+49.0K49.0K+$1M$1M
AVADEL PHARMACEUTICALS PLCNEW+82.5K82.5K+$1M$1M
SMTCSEMTECH CORPSOLD OUT−2.50M0−$69M$0
KINIKSA PHARMACEUTICALS LTDSOLD OUT−130.7K0−$3M$0
AVADEL PHARMACEUTICALS PLCSOLD OUT−82.5K0−$1M$0
HUMAHUMACYTE INCSOLD OUT−235.0K0−$730,850$0
TRAVERE THERAPEUTICS INCSOLD OUT−1.00M0−$629,500$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

23 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ARDXARDELYX INChistory →COM11.57%$6M856.7K
2IM8NINSMED INChistory →COM PAR $.018.59%$5M70.3K
3MISTMILESTONE PHARMACEUTICALS INhistory →COM5.63%$3M2.34M
4GONGERON CORPhistory →COM4.87%$3M630.0K
5MARINUS PHARMACEUTICALS INCCOM NEW4.51%$2M2.11M
6KINIKSA PHARMACEUTICALS INTLORD SHS CL A3.56%$2M104.7K
7SNDXSYNDAX PHARMACEUTICALS INChistory →COM2.43%$1M65.0K
8BBIOBRIDGEBIO PHARMA INChistory →COM2.26%$1M49.0K
9AVADEL PHARMACEUTICALS PLCCOM SHS2.11%$1M82.5K
10NBIXNEUROCRINE BIOSCIENCES INChistory →COM2.10%$1M8.3K
11FRXFENNEC PHARMACEUTICALS INChistory →COM1.89%$1M170.0K
12MLYSMINERALYS THERAPEUTICS INChistory →COM1.69%$924,30079.0K
13ENPHYS ACQUISITION CORPCL A ORD SHS1.56%$857,81378.1K
14JSPRJASPER THERAPEUTICS INChistory →COM NEW1.32%$726,40032.0K
15BLUEBIRD BIO INCCOM1.22%$667,540678.3K
160LSBURGERFI INTERNATIONAL INCCOM · *W EXP 12/16/2021.06%$583,6764.83M
17RGNXREGENXBIO INCCOM0.77%$424,12536.3K
18MCRB1EURSERES THERAPEUTICS INCCOM0.45%$246,643340.8K
19LUMOS PHARMA INCCOM0.38%$210,64290.8K
20MSFTMICROSOFT CORPCOM0.08%$44,695100
21SPRUCE BIOSCIENCES INCCOM0.07%$38,82875.0K
22BATLBATTALION OIL CORPCOM0.05%$24,7937.4K
23GOOGALPHABET INCCAP STK CL C0.03%$18,342100

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$17M35May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$19M39Feb 17, 202613F-HRchanges · EDGAR ↗
Q3 2025$18M27Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$15M19Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$16M21May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$19M19Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$45M25Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$55M27Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$179M32May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$200M30Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$224M31Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$221M30Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$243M31May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$703M32Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$454M41Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$878M40Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$431M35May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$373M33Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$533M38Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$579M34Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$550M30May 19, 2021RESTATEMENTchanges · EDGAR ↗
Q4 2020$519M24Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$456M24Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$412M24Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$379M25May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$1.1B26Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$897M26Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$1.0B24Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$1.1B24May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$636M35Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.